 |
- Lupin shares plunge 17% on US FDA warning letter Livemint
- Lupin shares end 17% lower as US drug regulator issues warning letters for two manufacturing units Scroll.in
- US FDA Warning Letter To Impact Launches, Not Supply, Says Lupin BloombergQuintFull coverage
|
No comments